Anti-CD1a CAR T cells to selectively target T-ALL
- 23 May 2019
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 133 (21) , 2246-2247
Abstract
In this issue of Blood, Sánchez-Martínez and colleagues present a novel approach to the treatment of T-acute lymphoblastic leukemia (T-ALL) using chimeric antigen receptor (CAR) T cells redirected against CD1a1 in in vitro and xenograft models.Keywords
This publication has 8 references indexed in Scilit:
- Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemiaBlood, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignanciesBlood Advances, 2017
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignanciesNature Medicine, 2017
- CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignanciesBlood, 2017
- Acute lymphoblastic leukemia: a comprehensive review and 2017 updateBlood Cancer Journal, 2017
- Management of adults with T-cell lymphoblastic leukemiaBlood, 2017
- A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignanciesBlood, 2015